Abstract:The cocirculation of coronavirus disease 2019 (COVID‐19) with other respiratory diseases, which is associated with a high risk of death, has attracted scant global attention. This study demonstrates a small, rapid (35–40 min), accessible (38–39 °C for all reactions), and automated platform for multiplex virus detection, and a high coinfection rate is found among patients with COVID‐19. The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 is profoundly influencing the global healthcare system and people's daily lives. The high resource consumption of coronavirus disease 2019 (COVID‐19) is resulting in insufficient surveillance of coinfection or resurgence of other critical respiratory epidemics, which is of public concern. To facilitate evaluation of the current coinfection situation, a microfluidic system (MAPnavi) is developed for the rapid (<40 min) and sensitive diagnosis of multiple respiratory viruses from swab samples in a fully sealed and automated manner, in which a nested‐recombinase polymerase amplification and the CRISPR‐based amplification system is first proposed to ensure the sensitivity and specificity. This novel system has a remarkably low limit of detection (50–200 copies mL−1) and is successfully applied to detect 171 clinical samples (98.5% positive predictive agreement; 100% negative predictive agreement), and the results identify 45.6% coinfection among clinical samples from patients with COVID‐19. This approach has the potential to shift diagnostic and surveillance efforts from targeted testing for a high‐priority virus to comprehensive testing of multiple virus sets and to greatly benefit the implementation of decentralized testing.

High-Throughput and Integrated CRISPR/Cas12a-Based Molecular Diagnosis Using a Deep Learning Enabled Microfluidic System

Portable all-in-one microfluidic system for CRISPR-Cas13a-based fully integrated multiplexed nucleic acid detection

Ultrafast Visual Nucleic Acid Detection with CRISPR/Cas12a and Rapid PCR in Single Capillary

Dual-CRISPR/Cas12a-Assisted RT-RAA for Ultrasensitive SARS-CoV-2 Detection on Automated Centrifugal Microfluidics

Integrated Dual Nucleic Acid Analysis by Slip Valve-Assisted Fluidic Chip Combined with CRISPR/Cas12a Detection

Development and application of sensitive, specific, and rapid CRISPR‐Cas13‐based diagnosis

CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern

Multiplexed lateral flow assay integrated with orthogonal CRISPR-Cas system for SARS-CoV-2 detection

Sensitive and Rapid Diagnosis of Respiratory Virus Coinfection Using a Microfluidic Chip‐Powered CRISPR/Cas12a System

Rapid and accurate detection of SARS-CoV-2 mutations using a Cas12a-based sensing platform

CRISPR/Cas12a-Assisted isothermal amplification for rapid and specific diagnosis of respiratory virus on an microfluidic platform

CRISPR-Mediated Profiling of Viral RNA at Single-Nucleotide Resolution

Rational Programming of Cas12a for Early-Stage Detection of COVID-19 by Lateral Flow Assay and Portable Real-Time Fluorescence Readout Facilities

Universally Stable and Precise CRISPR-LAMP Detection Platform for Precise Multiple Respiratory Tract Virus Diagnosis Including Mutant SARS-CoV-2 Spike N501Y

CESSAT: A chemical additive-enhanced single-step accurate CRISPR/Cas13 testing system for field-deployable ultrasensitive detection and genotyping of SARS-CoV-2 variants of concern

Rapid detection of SARS-CoV-2 with CRISPR-Cas12a

An engineered CRISPR-Cas12a variant and DNA-RNA hybrid guides enable robust and rapid COVID-19 testing

Isothermal Amplification and Ambient Visualization in a Single Tube for the Detection of SARS-CoV-2 Using Loop-Mediated Amplification and CRISPR Technology

Ultraspecific One-Pot CRISPR-Based "Green-Yellow-red" Multiplex Detection Strategy Integrated with Portable Cartridge for Point-of-Care Diagnosis.

Application of the amplification-free SERS-based CRISPR/Cas12a platform in the identification of SARS-CoV-2 from clinical samples